New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
Clinical and Molecular Hepatology
;
: 115-121, 2015.
Artigo
em Inglês
| WPRIM
| ID: wpr-128622
ABSTRACT
Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoemolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos de Fenilureia
/
Veia Porta
/
Quimioembolização Terapêutica
/
Niacinamida
/
Terapia Combinada
/
Carcinoma Hepatocelular
/
Trombose Venosa
/
Inibidores de Proteínas Quinases
/
Neoplasias Hepáticas
Tipo de estudo:
Guia de Prática Clínica
Limite:
Humanos
Idioma:
Inglês
Revista:
Clinical and Molecular Hepatology
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS